8. Primary outcome of Adalimumab therapy combined with immunosuppressive agent for the treatment of non-infectious uveitis in Vietnam
Main Article Content
Abstract
The purpose of this study was to assess the efficacy of Adalimumab (ADA) therapy combined with immunosuppressive agents (IS) for treatment of non-infectious uveitis. This was a non-controlled prospective clinical study of 31 eyes (16 patients) with non-infectious uveitis treated with ADA combined with IS during 24 weeks in Hanoi Medical University Hospital. The primary endpoint was the clinical response with treatment. The secondary endpoints included the study of macular thickness and of visual acuity, sparing effect of other treatment (ADA and IS) and adverse effects. At 24 weeks of treatment, a favorable clinical response was observed in 93.6% of eyes, with a complete response observed in 77.4% of eyes. Central macular thickness improved from 398 ± 172µm at baseline to 275 ± 35.7µm at 24 weeks (p = 0.001). Visual acuity also improved from 0.655 ± 0.474 (logMAR) at baseline to 0.344 ± 0.40 (logMAR) at 24 weeks (p = 0.094). The mean dose of methylprednisolone decreased from 27.4 ± 19.3mg at baseline to 6.14 ± 7.34mg at 24 weeks. Four patients experienced prolongation of dosing interval between ADA doses, which were initially given every 3 weeks. There was no serious adverse effect. In conclusion, the combined therapy of ADA and IS showed favorable results in terms of treatment response rates, improved visual acuity and macular thickness, reduced corticosteroid dose and promising ADA dosing interval prolongation for patients with non-infectious uveitis.
Article Details
Keywords
Non-infectious uveitis, Adalimumab, Immunosuppressive drugs
References
2. Ad D, Jt R, Ha AD, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018;125(5). doi:10.1016/j.ophtha.2017.11.017
3. Gangaputra SS, Newcomb CW, Joffe MM, et al. Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases. Am J Ophthalmol. 2019;208:68-75. doi:10.1016/j.ajo.2019.07.008
4. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016;375:932-943. doi:10.1056/NEJMoa1509852
5. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet Lond Engl. 2016;388(10050):1183-1192. doi:10.1016/S0140-6736(16)31339-3
6. Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet’s Disease. Ophthalmology. 2018;125(9):1444-1451. doi:10.1016/j.ophtha.2018.02.020
7. Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies. Ophthalmology. 2016;123(12):2618-2625. doi:10.1016/j.ophtha. 2016.08.025
8. Mercier AE, Ribeiro E, Korobelnik JF, et al. Efficacy of Anti-Tnf-Α Therapy for the Treatment of Non-Infectious Uveitis: A Retrospective Study of 21 Patients. Ocul Immunol Inflamm. 2018;26(3):477-484. doi:10.1080/09273948.2016.1236968
9. Hiyama T, Harada Y, Kiuchi Y. Clinical Characteristics and Efficacy of Adalimumab and Low-Dose Methotrexate Combination Therapy in Patients With Vogt-Koyanagi-Harada Disease. Front Med. 2022;8:730215. doi:10.3389/fmed.2021.730215
10. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637-1646. doi:10.1056/NEJMoa1614160
11. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina Phila Pa. 2007;27(4):399-413. doi:10.1097/MAJ.0b013e3180318fbc
12. Vallet H, Seve P, Biard L, et al. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis Rheumatol. 2016;68(6):1522-1530. doi:10.1002/art.39667
13. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826-1832. doi:10.1016/j.ophtha. 2008.04.026
14. Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428-1437. doi:10.1136/annr heumdis-2016-209201
15. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. doi:10.1136/annrheumdis-2020-217159
16. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: A RCT. Health Technol Assess Winch Engl. 2019;23(15):1-140. doi:10.3310/hta23150
17. Lian F, Zhou J, Wei C, et al. Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population. Clin Rheumatol. 2015;34(11):1913-1920. doi:10.1007/s10067-015-2989-8